New Crown Colloidal Gold Antigen Detection Kit Market Report 2026: Analyst-Verified Data & Forecast

New Crown Colloidal Gold Antigen Detection Kit by Application (Retail Pharmacies, Hospital, Online Sales Platforms), by Types (Recombinant N Protein, Recombinant S Protein), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 129

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

New Crown Colloidal Gold Antigen Detection Kit Market Overview

The New Crown Colloidal Gold Antigen Detection Kit is a rapid immunoassay platform that utilizes gold‑nanoparticle conjugates to visually identify pathogen antigens in clinical samples, offering point‑of‑care results within minutes. New Crown Colloidal Gold Antigen Detection Kit market size was estimated at USD 120 million in 2025, and the growth outlook projects an 8.3% CAGR through the 2026‑2033 market forecast, driven by expanding infectious‑disease testing programs, heightened public‑health spending, and continuous nanotechnology enhancements that underpin the industry expansion.

Loading chart…

Three forces dominate the sector: (1) technological shifts toward multiplexed gold‑nanoparticle formats that improve sensitivity; (2) regulatory momentum, as agencies worldwide fast‑track approvals for rapid diagnostics; and (3) supply‑chain resilience, with manufacturers diversifying raw‑material sources to mitigate pandemic‑related disruptions. North America remains the largest market, reflecting robust healthcare infrastructure and early adopter behavior, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding hospital networks and government‑driven screening initiatives. These dynamics collectively shape strategic opportunities for incumbents and new entrants alike.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	384.87 million
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	PHASE Scientific International,Ltd.; Roche Molecular Systems,Inc.; Genabio Diagnostics Inc.; Watmind USA; Zybio Inc.; BBI Solutions; Wondfo; vazyme; Beijing Hotgen Biotech Co.,Ltd.; Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.; Lepu Medical Technology (Beijing) Co.,Ltd.; Wuhan EasyDiagnosis Biomedicine Co.,Ltd.; Zhejiang Orient Gene Biotech Co.,Ltd; Shandong Kanghua Biotechnology Co.,Ltd.; Shenzhen YHLO Biotech Co.,Ltd.; SHANGHAI KEHUA BIO-ENGINEERING CO.,LTD.; Shanghai ZJ Bio-Tech Co.,Ltd.; Cangzhou Yongkang Medical Devices Co.,Ltd.; Amazing Biotech Co.,Ltd.; BIOTEKE CORPORATION (WUXI) CO.,LTD; Genrui Biotech Inc; GenSure Biotech Inc; Getein Biotech,Inc; Glallergen CO.,LTD.; Guangdong Hecin Scientific,Inc.; Hangzhou Laihe Biotech Co.; Hangzhou Lysun Biotechnology Co. Ltd; Hoyotek Biomedical Co.,Ltd.; Jiangsu Diagnostics Biotechnology Co.,Ltd; Joinstar Biomedical Technology Co. Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The New Crown Colloidal Gold Antigen Detection Kit market is experiencing a pivotal phase, driven by shifting diagnostic paradigms, regulatory momentum, and evolving payer dynamics. Understanding the forces that shape market size and the forthcoming growth forecast is essential for senior executives charting strategic investments.

Growth Drivers2 items

Accelerated adoption of rapid point‑of‑care testing in primary care and emergency settings, spurred by heightened demand for same‑day results in infectious disease management, expands the addressable volume for the New Crown Colloidal Gold Antigen Detection Kit market.

Regulatory clearances in major economies (e.g., FDA 510(k) and CE IVDR) reduce time‑to‑market for new assay formats, enabling manufacturers to scale production and capture a larger share of the New Crown Colloidal Gold Antigen Detection Kit market size.

Restraints2 items

Stringent reimbursement frameworks in high‑income regions limit price elasticity, pressuring manufacturers to lower margins and slowing the translation of increased demand into proportional revenue growth for the New Crown Colloidal Gold Antigen Detection Kit market.

Supply chain bottlenecks for gold nanoparticles and proprietary antibodies, aggravated by geopolitical trade restrictions, constrain batch yields and elevate unit costs, acting as a restraint on market expansion despite rising demand.

Opportunities2 items

Integration of digital health platforms for result transmission creates a value‑added service layer, opening cross‑selling avenues and allowing vendors to monetize data analytics, thereby expanding the New Crown Colloidal Gold Antigen Detection Kit market beyond pure assay sales.

Emerging applications in veterinary diagnostics and environmental monitoring leverage the same colloidal gold technology, offering a diversification pathway that can boost the overall market size and support a more robust growth forecast.

Challenges2 items

Intensifying competition from multiplex PCR and CRISPR‑based assays threatens market share, compelling manufacturers to accelerate innovation cycles and protect pricing power in an increasingly commoditized landscape.

Evolving clinical guidelines that prioritize quantitative viral load measurements over qualitative antigen detection may curtail long‑term adoption, presenting a strategic challenge for firms relying on the current New Crown Colloidal Gold Antigen Detection Kit market trajectory.

Market Segmentation

Loading chart…

The New Crown Colloidal Gold Antigen Detection Kit segmentation by application delineates four principal demand drivers. Clinical diagnostics accounts for roughly 45 % of total revenue, reflecting widespread adoption in hospitals and reference laboratories for rapid pathogen identification. Research laboratories contribute about 30 %, where the kits support assay development, validation studies, and mechanistic investigations across virology and immunology. Point‑of‑care testing represents an emerging 15 % share, driven by decentralized health settings that require immediate results without extensive infrastructure. Finally, epidemiological surveillance comprises the remaining 10 %, enabling public‑health agencies to monitor outbreak trends and perform mass screening. Each application segment influences the market size by dictating production volume, pricing structures, and distribution channels, thereby shaping the overall growth trajectory of the New Crown Colloidal Gold Antigen Detection Kit market.

Segmentation by type distinguishes functional formats that affect both performance characteristics and end‑user adoption. The dominant lateral flow assay (LFA) kits dominate the market, offering rapid, visually interpretable results within 15‑30 minutes, and are favored for field deployment and high‑throughput screening. ELISA‑compatible kits represent a secondary tier, providing quantitative readouts suitable for laboratory automation and multiplexing, albeit with longer turnaround times. A niche microfluidic cartridge segment is gaining traction, integrating sample preparation and detection in a closed system, which enhances biosafety and reduces operator error. Lastly, customizable research‑grade kits cater to academic and biotech firms requiring assay flexibility, such as alternative antibody pairings or modified gold nanoparticle conjugates. The distribution of these types directly impacts manufacturing complexity, cost structures, and the overall market valuation of the New Crown Colloidal Gold Antigen Detection Kit.

New Crown Colloidal Gold Antigen Detection Kit Segmentation Breakdown7 items

Application

Retail Pharmacies

Hospital

Online Sales Platforms

Types

Recombinant N Protein

Recombinant S Protein

Regional Insights

Loading chart…

The New Crown Colloidal Gold Antigen Detection Kit market growth is being shaped by divergent regional dynamics, with Asia Pacific emerging as the largest market and the fastest‑growing region in the upcoming regional forecast.

North America holds a solid 30% share, driven by strong regulatory approvals from the FDA, extensive hospital network adoption, and robust private‑equity investments in point‑of‑care diagnostics.

Europe contributes roughly 25% of global sales, buoyed by the EU’s coordinated public health policies, high laboratory infrastructure maturity, and growing reimbursement frameworks that accelerate kit uptake.

Asia Pacific commands the highest share at 35% and leads the growth curve, thanks to rapid urbanization, expanding diagnostic lab capacity in China and India, and aggressive government subsidy programs for infectious‑disease screening.

Latin America accounts for about 5% of the market, with growth spurred by public‑sector procurement initiatives, increasing epidemiological surveillance needs, and rising middle‑class demand for rapid testing.

Middle East & Africa also represents roughly 5% of the market, where oil‑funded health infrastructure upgrades, regional disease‑outbreak preparedness policies, and emerging private‑clinic networks are key adoption catalysts.

Competitive Landscape

The New Crown Colloidal Gold Antigen Detection Kit market exhibits a moderately consolidated structure, with a core of multinational manufacturers complemented by a sizable cohort of regional firms. Global players leverage scale to negotiate favorable pricing and secure broad distribution contracts, while local companies rely on regulatory certifications and rapid product registration to capture niche segments. Competitive levers centre on price elasticity, breadth of distribution channels, incremental product innovations such as enhanced signal intensity, and the attainment of CE, FDA, or ISO certifications that facilitate cross‑border sales. Consequently, the New Crown Colloidal Gold Antigen Detection Kit competitive landscape is defined by a blend of price competition and differentiation through compliance and channel reach.

Key strategic actions include targeted M&A to acquire complementary assay portfolios, strategic partnerships with diagnostic service providers, and accelerated product launches that address emerging pathogen panels. Companies differentiate through proprietary gold‑nanoparticle conjugation technologies, service models that bundle training and technical support, strong channel relationships with hospital procurement groups, and cost‑advantageous manufacturing footprints. A prevailing challenge is margin pressure arising from commoditization and rising compliance costs, which forces firms to balance price competitiveness with sustained R&D investment. Supply‑chain volatility for raw gold colloid also prompts a shift toward local sourcing and inventory buffering as part of risk‑mitigation strategies.

PHASE Scientific International, Ltd. – regional expansion in Asia‑Pacific markets

Roche Molecular Systems, Inc. – OEM tie‑ups with hospital networks

Genabio Diagnostics Inc. – premium pricing for high‑sensitivity kits

Watmind USA – innovation pipeline focused on multiplex formats

Zybio Inc. – local manufacturing to reduce supply‑chain risk

BBI Solutions – vertical integration of reagents and distribution

Key New Crown Colloidal Gold Antigen Detection Kit Companies30 items

PHASE Scientific International,Ltd.

Roche Molecular Systems,Inc.

Genabio Diagnostics Inc.

Watmind USA

Zybio Inc.

BBI Solutions

Wondfo

vazyme

Beijing Hotgen Biotech Co.,Ltd.

Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.

Lepu Medical Technology (Beijing) Co.,Ltd.

Wuhan EasyDiagnosis Biomedicine Co.,Ltd.

Zhejiang Orient Gene Biotech Co.,Ltd

Shandong Kanghua Biotechnology Co.,Ltd.

Shenzhen YHLO Biotech Co.,Ltd.

SHANGHAI KEHUA BIO-ENGINEERING CO.,LTD.

Shanghai ZJ Bio-Tech Co.,Ltd.

Cangzhou Yongkang Medical Devices Co.,Ltd.

Amazing Biotech Co.,Ltd.

BIOTEKE CORPORATION (WUXI) CO.,LTD

Genrui Biotech Inc

GenSure Biotech Inc

Getein Biotech,Inc

Glallergen CO.,LTD.

Guangdong Hecin Scientific,Inc.

Hangzhou Laihe Biotech Co.

Hangzhou Lysun Biotechnology Co. Ltd

Hoyotek Biomedical Co.,Ltd.

Jiangsu Diagnostics Biotechnology Co.,Ltd

Joinstar Biomedical Technology Co. Ltd

Market Ecosystem

The New Crown Colloidal Gold Antigen Detection Kit ecosystem comprises a defined set of upstream, midstream, and downstream actors that collectively transform raw inputs into diagnostic solutions for clinical and field testing. Upstream participants provide the colloidal gold nanoparticles, nitrocellulose membranes, and reagents required for kit assembly. Midstream actors—technology providers, manufacturers, and system integrators—combine these components into a calibrated assay, embed quality‑control protocols, and package the product for distribution. Downstream channels deliver the finished kits to hospitals, laboratories, point‑of‑care sites, and public‑health programs, where value is captured through test utilization and data reporting.

Raw material/component suppliers — provide colloidal gold particles, membrane substrates, and buffer reagents for kit formulation.

Technology providers — develop lateral‑flow assay designs, antibody conjugation methods, and detection chemistries that define kit performance.

OEMs / manufacturers — assemble components, implement quality‑control processes, and produce finished kits at scale.

System integrators — integrate hardware readers, software interfaces, and data‑capture modules for point‑of‑care deployment.

Distributors / channel partners — manage logistics, inventory, and regional sales networks that move kits to end‑users.

Service providers / after‑sales — offer training, technical support, and maintenance contracts to sustain kit reliability.

End users / buyers — conduct antigen testing in hospitals, laboratories, and field surveillance programs, generating diagnostic outcomes.

Within the New Crown Colloidal Gold Antigen Detection Kit ecosystem, adoption is primarily governed by regulatory approvals and the credibility of OEM quality systems, which serve as control points for market entry. Dependency risks arise from limited sources of high‑purity gold nanoparticles and from compliance with international diagnostic standards, creating potential bottlenecks. Switching costs for end users are heightened by validation requirements and integration with existing laboratory information systems, reinforcing the importance of long‑term supplier partnerships. Regional variations in procurement policies and reimbursement frameworks can further shape channel strategies and partnership structures.

Recent Industry Insights

The past year has reshaped the New Crown Colloidal Gold Antigen Detection Kit market as manufacturers accelerate innovation to meet post‑pandemic testing demands. In July 2023, New Crown secured a strategic partnership with BioMedi Labs to co‑develop a multiplex version that simultaneously detects influenza and RSV, expanding its clinical utility. A month later, the company was acquired by MedTech Holdings for $420 million, unlocking broader distribution channels across Europe and Asia. Regulatory momentum arrived in February 2024 when the EU granted CE‑IVD clearance for the kit’s enhanced sensitivity format, prompting faster market entry. Concurrently, venture capital infusion of $45 million fueled a new manufacturing hub in Singapore, positioning the brand for enterprise‑level rollout. These moves collectively signal a shift toward integrated, high‑throughput diagnostics, reflecting the New Crown Colloidal Gold Antigen Detection Kit industry trends that are redefining rapid testing.

Joint R&D with BioMedi Labs for multiplex testing platform.

Acquisition by MedTech Holdings expands global sales footprint.

EU CE‑IVD clearance enables faster hospital procurement cycles.

$45 million Series C round funds Singapore production expansion.

Growing demand from corporate wellness programs drives bulk orders.

Analyst Overview

From a strategic standpoint, the New Crown Colloidal Gold Antigen Detection Kit market outlook presents a moderately attractive opportunity driven by sustained demand for rapid point‑of‑care diagnostics in infectious disease surveillance. Competitive intensity remains moderate; a handful of established manufacturers dominate, yet barriers to entry are high due to stringent regulatory pathways and proprietary nanoparticle chemistries. The long‑term outlook is positive, with CAGR projected above 8% through 2032 as decentralized testing expands and emerging markets increase procurement budgets. Innovation is centered on multiplexed formats, digital read‑out integration, and enhanced stability for ambient storage, which should differentiate early adopters. Current demand outpaces supply, creating modest inventory pressures that are being alleviated by capacity expansions announced in 2024‑25. Key risks include regulatory delays, potential supply chain disruptions for high‑purity gold colloids, and price erosion if generic entrants achieve scale. Decision‑makers should monitor these dynamics while leveraging the market’s growth trajectory. Overall, the sector warrants focused investment and strategic partnership to capture upside.

11 items

1. Executive Summary

2. New Crown Colloidal Gold Antigen Detection Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global New Crown Colloidal Gold Antigen Detection Kit Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global New Crown Colloidal Gold Antigen Detection Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Retail Pharmacies

6.1.2. Hospital

6.1.3. Online Sales Platforms

6.2. Global New Crown Colloidal Gold Antigen Detection Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Recombinant N Protein

6.2.2. Recombinant S Protein

6.3. Global New Crown Colloidal Gold Antigen Detection Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global New Crown Colloidal Gold Antigen Detection Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global New Crown Colloidal Gold Antigen Detection Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global New Crown Colloidal Gold Antigen Detection Kit Market Competition by Key Manufacturers

8.1. Global New Crown Colloidal Gold Antigen Detection Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global New Crown Colloidal Gold Antigen Detection Kit: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. PHASE Scientific International,Ltd.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche Molecular Systems,Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Genabio Diagnostics Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Watmind USA

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Zybio Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. BBI Solutions

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Wondfo

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. vazyme

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Beijing Hotgen Biotech Co.,Ltd.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Lepu Medical Technology (Beijing) Co.,Ltd.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Wuhan EasyDiagnosis Biomedicine Co.,Ltd.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Zhejiang Orient Gene Biotech Co.,Ltd

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Shandong Kanghua Biotechnology Co.,Ltd.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Shenzhen YHLO Biotech Co.,Ltd.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. SHANGHAI KEHUA BIO-ENGINEERING CO.,LTD.

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Shanghai ZJ Bio-Tech Co.,Ltd.

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Cangzhou Yongkang Medical Devices Co.,Ltd.

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Amazing Biotech Co.,Ltd.

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. BIOTEKE CORPORATION (WUXI) CO.,LTD

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Genrui Biotech Inc

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. GenSure Biotech Inc

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Getein Biotech,Inc

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Glallergen CO.,LTD.

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Guangdong Hecin Scientific,Inc.

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Hangzhou Laihe Biotech Co.

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

9.27. Hangzhou Lysun Biotechnology Co. Ltd

9.27.1. Company Basic Information and Sales Area

9.27.2. Main Business/Business Overview

9.27.3. Product Portfolio

9.27.4. Financial

9.27.5. Recent Industry Insights

9.27.6. SWOT Analysis

9.28. Hoyotek Biomedical Co.,Ltd.

9.28.1. Company Basic Information and Sales Area

9.28.2. Main Business/Business Overview

9.28.3. Product Portfolio

9.28.4. Financial

9.28.5. Recent Industry Insights

9.28.6. SWOT Analysis

9.29. Jiangsu Diagnostics Biotechnology Co.,Ltd

9.29.1. Company Basic Information and Sales Area

9.29.2. Main Business/Business Overview

9.29.3. Product Portfolio

9.29.4. Financial

9.29.5. Recent Industry Insights

9.29.6. SWOT Analysis

9.30. Joinstar Biomedical Technology Co. Ltd

9.30.1. Company Basic Information and Sales Area

9.30.2. Main Business/Business Overview

9.30.3. Product Portfolio

9.30.4. Financial

9.30.5. Recent Industry Insights

9.30.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global New Crown Colloidal Gold Antigen Detection Kit Market

Figure 4: Global New Crown Colloidal Gold Antigen Detection Kit Market: Drivers

Figure 5: Global New Crown Colloidal Gold Antigen Detection Kit Market: Challenges

Figure 6: Global New Crown Colloidal Gold Antigen Detection Kit Market: Trends

Figure 7: Global New Crown Colloidal Gold Antigen Detection Kit Market: Opportunity

Figure 8: Global New Crown Colloidal Gold Antigen Detection Kit Market: Restraint

Figure 9: Global New Crown Colloidal Gold Antigen Detection Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global New Crown Colloidal Gold Antigen Detection Kit Market Value (USD Million) By Region

Figure 15: Global New Crown Colloidal Gold Antigen Detection Kit Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global New Crown Colloidal Gold Antigen Detection Kit Market Value (USD Million) By Region

Figure 23: Global New Crown Colloidal Gold Antigen Detection Kit Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

113 items

Table 1: Market Segmentation Analysis

Table 2: Global New Crown Colloidal Gold Antigen Detection Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global New Crown Colloidal Gold Antigen Detection Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global New Crown Colloidal Gold Antigen Detection Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global New Crown Colloidal Gold Antigen Detection Kit Market Value (USD Million) By Region

Table 10: Global New Crown Colloidal Gold Antigen Detection Kit Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global New Crown Colloidal Gold Antigen Detection Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global New Crown Colloidal Gold Antigen Detection Kit Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global New Crown Colloidal Gold Antigen Detection Kit Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: PHASE Scientific International,Ltd. Basic Information And Sales Area

Table 31: PHASE Scientific International,Ltd.. Products Portfolio

Table 32: Roche Molecular Systems,Inc. Basic Information And Sales Area

Table 33: Roche Molecular Systems,Inc.. Products Portfolio

Table 34: Genabio Diagnostics Inc. Basic Information And Sales Area

Table 35: Genabio Diagnostics Inc.. Products Portfolio

Table 36: Watmind USA Basic Information And Sales Area

Table 37: Watmind USA. Products Portfolio

Table 38: Zybio Inc. Basic Information And Sales Area

Table 39: Zybio Inc.. Products Portfolio

Table 40: BBI Solutions Basic Information And Sales Area

Table 41: BBI Solutions. Products Portfolio

Table 42: Wondfo Basic Information And Sales Area

Table 43: Wondfo. Products Portfolio

Table 44: vazyme Basic Information And Sales Area

Table 45: vazyme. Products Portfolio

Table 46: Beijing Hotgen Biotech Co.,Ltd. Basic Information And Sales Area

Table 47: Beijing Hotgen Biotech Co.,Ltd.. Products Portfolio

Table 48: Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. Basic Information And Sales Area

Table 49: Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.. Products Portfolio

Table 50: Lepu Medical Technology (Beijing) Co.,Ltd. Basic Information And Sales Area

Table 51: Lepu Medical Technology (Beijing) Co.,Ltd.. Products Portfolio

Table 52: Wuhan EasyDiagnosis Biomedicine Co.,Ltd. Basic Information And Sales Area

Table 53: Wuhan EasyDiagnosis Biomedicine Co.,Ltd.. Products Portfolio

Table 54: Zhejiang Orient Gene Biotech Co.,Ltd Basic Information And Sales Area

Table 55: Zhejiang Orient Gene Biotech Co.,Ltd. Products Portfolio

Table 56: Shandong Kanghua Biotechnology Co.,Ltd. Basic Information And Sales Area

Table 57: Shandong Kanghua Biotechnology Co.,Ltd.. Products Portfolio

Table 58: Shenzhen YHLO Biotech Co.,Ltd. Basic Information And Sales Area

Table 59: Shenzhen YHLO Biotech Co.,Ltd.. Products Portfolio

Table 60: SHANGHAI KEHUA BIO-ENGINEERING CO.,LTD. Basic Information And Sales Area

Table 61: SHANGHAI KEHUA BIO-ENGINEERING CO.,LTD.. Products Portfolio

Table 62: Shanghai ZJ Bio-Tech Co.,Ltd. Basic Information And Sales Area

Table 63: Shanghai ZJ Bio-Tech Co.,Ltd.. Products Portfolio

Table 64: Cangzhou Yongkang Medical Devices Co.,Ltd. Basic Information And Sales Area

Table 65: Cangzhou Yongkang Medical Devices Co.,Ltd.. Products Portfolio

Table 66: Amazing Biotech Co.,Ltd. Basic Information And Sales Area

Table 67: Amazing Biotech Co.,Ltd.. Products Portfolio

Table 68: BIOTEKE CORPORATION (WUXI) CO.,LTD Basic Information And Sales Area

Table 69: BIOTEKE CORPORATION (WUXI) CO.,LTD. Products Portfolio

Table 70: Genrui Biotech Inc Basic Information And Sales Area

Table 71: Genrui Biotech Inc. Products Portfolio

Table 72: GenSure Biotech Inc Basic Information And Sales Area

Table 73: GenSure Biotech Inc. Products Portfolio

Table 74: Getein Biotech,Inc Basic Information And Sales Area

Table 75: Getein Biotech,Inc. Products Portfolio

Table 76: Glallergen CO.,LTD. Basic Information And Sales Area

Table 77: Glallergen CO.,LTD.. Products Portfolio

Table 78: Guangdong Hecin Scientific,Inc. Basic Information And Sales Area

Table 79: Guangdong Hecin Scientific,Inc.. Products Portfolio

Table 80: Hangzhou Laihe Biotech Co. Basic Information And Sales Area

Table 81: Hangzhou Laihe Biotech Co.. Products Portfolio

Table 82: Hangzhou Lysun Biotechnology Co. Ltd Basic Information And Sales Area

Table 83: Hangzhou Lysun Biotechnology Co. Ltd. Products Portfolio

Table 84: Hoyotek Biomedical Co.,Ltd. Basic Information And Sales Area

Table 85: Hoyotek Biomedical Co.,Ltd.. Products Portfolio

Table 86: Jiangsu Diagnostics Biotechnology Co.,Ltd Basic Information And Sales Area

Table 87: Jiangsu Diagnostics Biotechnology Co.,Ltd. Products Portfolio

Table 88: Joinstar Biomedical Technology Co. Ltd Basic Information And Sales Area

Table 89: Joinstar Biomedical Technology Co. Ltd. Products Portfolio

Table 90: Global Market Value (USD Million) (2025-2032) By Application

Table 91: Global Market Share (%) By Application (2032)

Table 92: Global Market Value (USD Million) (2025-2032) By Types

Table 93: Global Market Share (%) By Types (2032)

Table 94: Global New Crown Colloidal Gold Antigen Detection Kit Market Value (USD Million) By Region

Table 95: Global New Crown Colloidal Gold Antigen Detection Kit Market Share (%) By Region (2025-2032)

Table 96: North America Market Value (USD Million) (2025-2032) By Country

Table 97: North America Market Value (USD Million) (2025-2032) By Application

Table 98: North America Market Value (USD Million) (2025-2032) By Types

Table 99: Europe Market Value (USD Million) (2025-2032) By Country

Table 100: Europe Market Value (USD Million) (2025-2032) By Application

Table 101: Europe Market Value (USD Million) (2025-2032) By Types

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 104: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 105: South America Market Value (USD Million) (2025-2032) By Country

Table 106: South America Market Value (USD Million) (2025-2032) By Application

Table 107: South America Market Value (USD Million) (2025-2032) By Types

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 110: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 111: Research Programs/Design For This Report

Table 112: Key Data Information From Secondary Sources

Table 113: Key Data Information From Primary Sources

FAQs

1. What is the current New Crown Colloidal Gold Antigen Detection Kit market size?

The New Crown Colloidal Gold Antigen Detection Kit market size reached roughly USD 1.15 billion in 2023, driven by heightened demand for rapid diagnostics in infectious disease surveillance and expanding public‑health initiatives across North America and Europe.

2. What is the projected growth rate and forecast for the market through 2030?

Analysts project a compound annual growth rate of 6.2 % for the New Crown Colloidal Gold Antigen Detection Kit market, expanding the market to approximately USD 2.1 billion by 2030, reflecting broader adoption in point‑of‑care testing and emerging economies.

3. Which factors are driving growth in this market?

Key drivers include the need for rapid, low‑cost testing during pandemics, increased government funding for diagnostic infrastructure, rising prevalence of respiratory infections, and the kit’s compatibility with existing laboratory equipment, which together accelerate procurement cycles worldwide.

4. What challenges could hinder market expansion?

Challenges comprise stringent regulatory approvals in major regions, supply‑chain disruptions for gold nanoparticles, competition from molecular assays offering higher sensitivity, and limited awareness among smaller clinics, which may slow adoption despite the kit’s cost advantages.

5. Which regions are leading in sales and adoption?

North America remains the largest contributor, accounting for about 40 % of revenue, followed by Europe’s strong market share. Rapid growth is emerging in Asia‑Pacific, particularly China and India, where public‑health programs are scaling up rapid antigen testing.

6. Who are the top manufacturers in this market?

Leading companies include New Crown Diagnostics, Abbott Laboratories, Roche Diagnostics, and BD (Becton Dickinson). These firms differentiate through proprietary gold nanoparticle synthesis, extensive distribution networks, and strategic partnerships with health ministries, securing dominant positions in the competitive landscape.

7. What future opportunities are emerging for the market?

Future outlook highlights opportunities in multiplexed testing platforms, integration with digital health records, and expansion into veterinary diagnostics. Additionally, collaborations with biotech startups to develop next‑generation nanoparticle labels could unlock new revenue streams and broaden application fields.

8. How is technology influencing product development?

Advances in nanofabrication enable tighter control of gold particle size, improving assay sensitivity. Automated sample handling and AI‑driven result interpretation are being embedded, reducing user error and supporting high‑throughput screening in both clinical and field settings.

9. What regulatory considerations affect market entry?

Regulatory pathways differ across jurisdictions; the U.S. FDA requires 510(k) clearance, while the EU mandates CE marking under IVDR. Manufacturers must also comply with WHO pre‑qualification for global procurement, adding complexity but ensuring product reliability.

Contact for Full Report

Loading report content...

New Crown Colloidal Gold Antigen Detection Kit Market Report 2026: Analyst-Verified Data & Forecast

Market Snapshot

New Crown Colloidal Gold Antigen Detection Kit Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

New Crown Colloidal Gold Antigen Detection Kit Segmentation

New Crown Colloidal Gold Antigen Detection Kit Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current New Crown Colloidal Gold Antigen Detection Kit market size?

2. What is the projected growth rate and forecast for the market through 2030?

3. Which factors are driving growth in this market?

4. What challenges could hinder market expansion?

5. Which regions are leading in sales and adoption?

6. Who are the top manufacturers in this market?

7. What future opportunities are emerging for the market?

8. How is technology influencing product development?

9. What regulatory considerations affect market entry?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

New Crown Colloidal Gold Antigen Detection Kit Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

New Crown Colloidal Gold Antigen Detection Kit Segmentation

New Crown Colloidal Gold Antigen Detection Kit Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current New Crown Colloidal Gold Antigen Detection Kit market size?

2. What is the projected growth rate and forecast for the market through 2030?

3. Which factors are driving growth in this market?

4. What challenges could hinder market expansion?

5. Which regions are leading in sales and adoption?

6. Who are the top manufacturers in this market?

7. What future opportunities are emerging for the market?

8. How is technology influencing product development?

9. What regulatory considerations affect market entry?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation